Expanding the Treatment Landscape for

Recurrent Low-Grade Serous Ovarian Cancer
Industry Supported Symposium

Expert opinion leaders will engage with important educational updates and discussions on the evolving clinical landscape of low-grade serous ovarian cancer (LGSOC). LGSOC continues to have a high mortality rate, and better treatment options remain an unmet need. Recent studies indicate that therapies in the recurrent space support combination therapy treatment options. Expanding and improving the treatment landscape for recurrent LGSOC with practice changing medicines is a long-term goal to continue to enhance efficacy as well as quality of life for patients.

This non-promotional symposium is organized and funded by Verastem in collaboration with The GOG Foundation, Inc.

Target Audience

The target audience for this activity is community and academic gynecologic oncologists, oncologists, advanced practitioners (NP/PA/PharmD), and other providers who treat patients with gynecologic malignancies.

Learning Objectives

Upon completion of the activities in this series, learners will demonstrate Increased knowledge regarding:

• Highlight Clinical Landscape and Learn About Challenges as it Pertains to Recurrent LGSOC
• Understand Most Recent Clinical Trial Data and Treatment Options in Recurrent LGSOC
• Share Best Practices and Discuss Future Directions in Treatment Landscape

Moderator

Dr. Pedro T. Ramirez

Faculty

Prof. Susana Banerjee

Dr. Rachel N. Grisham

Agenda

Expanding the Treatment Landscape for Recurrent Low-Grade Serous Ovarian Cancer, an Industry Supported Symposium at the IGCS 2024 Annual Global Meeting

This session is not included in the main event CME/CPD credit.

View Recording